John Charles A Lacson1, Revery P Barnes2, Hossein Bahrami3,4,5,6. 1. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 2. Department of Family Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 3. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. hbahrami@med.usc.edu. 4. Division of Cardiovascular Medicine, Department of Medicine, University of Southern California, Los Angeles, CA, USA. hbahrami@med.usc.edu. 5. Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. hbahrami@med.usc.edu. 6. Division of Cardiology, Department of Medicine, Keck School of Medicine of University of Southern California, 2020 Zonal Ave, Los Angeles, CA, 90033, USA. hbahrami@med.usc.edu.
Abstract
PURPOSE OF REVIEW: Introduction of combination antiretroviral therapy (ART) has increased the life expectancy of patients with HIV infection, allowing them to live longer with this chronic medical condition and consequently experiencing conditions such as cardiovascular diseases (CVDs). Several studies have investigated the increased risk of CVD in people living with HIV (PLWH). However, less is known about the exact mechanisms involved in this increased risk. Also, specific guidelines for management of CVD in PLWH have not been developed yet. In this article, we review the recent literature on the mechanisms involved in pathogenesis of CVD in PLWH, with an emphasis on coronary artery disease (CAD). RECENT FINDINGS: Although initial studies suspected the increased prevalence of traditional CVD risk factors and side effects of ART to be involved in the increased CVD risk in PLWH, recent studies have uncovered the important role of chronic persistent inflammation in this increased risk. In addition, biomarkers of inflammation have been associated with both CVD events and subclinical CAD in this population. Lastly, recent studies and ongoing clinical trials have been investigating medical interventions that aim to reduce inflammation and cardiovascular events. Different mechanisms of inflammation have been examined in PLWH, including subclinical viremia, microbial translocation, and coinfection with other pathogens such as cytomegalovirus. Although inflammatory biomarkers have been consistently associated with CVD and subclinical CVD outcomes, their prognostic value is unknown. Recent and ongoing trials are exploring the benefits of anti-inflammatory drugs, statins, and antimicrobial translocation drugs on both inflammation and CVD risk among PLWH.
PURPOSE OF REVIEW: Introduction of combination antiretroviral therapy (ART) has increased the life expectancy of patients with HIV infection, allowing them to live longer with this chronic medical condition and consequently experiencing conditions such as cardiovascular diseases (CVDs). Several studies have investigated the increased risk of CVD in people living with HIV (PLWH). However, less is known about the exact mechanisms involved in this increased risk. Also, specific guidelines for management of CVD in PLWH have not been developed yet. In this article, we review the recent literature on the mechanisms involved in pathogenesis of CVD in PLWH, with an emphasis on coronary artery disease (CAD). RECENT FINDINGS: Although initial studies suspected the increased prevalence of traditional CVD risk factors and side effects of ART to be involved in the increased CVD risk in PLWH, recent studies have uncovered the important role of chronic persistent inflammation in this increased risk. In addition, biomarkers of inflammation have been associated with both CVD events and subclinical CAD in this population. Lastly, recent studies and ongoing clinical trials have been investigating medical interventions that aim to reduce inflammation and cardiovascular events. Different mechanisms of inflammation have been examined in PLWH, including subclinical viremia, microbial translocation, and coinfection with other pathogens such as cytomegalovirus. Although inflammatory biomarkers have been consistently associated with CVD and subclinical CVD outcomes, their prognostic value is unknown. Recent and ongoing trials are exploring the benefits of anti-inflammatory drugs, statins, and antimicrobial translocation drugs on both inflammation and CVD risk among PLWH.
Authors: Frank O Pettersen; Eirik A Torheim; Anders E A Dahm; Ingeborg S Aaberge; Andreas Lind; Malin Holm; Einar M Aandahl; Per M Sandset; Kjetil Taskén; Dag Kvale Journal: J Virol Date: 2011-04-13 Impact factor: 5.103
Authors: Matthew S Freiberg; Chung-Chou H Chang; Melissa Skanderson; Kathleen McGinnis; Lewis H Kuller; Kevin L Kraemer; David Rimland; Matthew B Goetz; Adeel A Butt; Maria C Rodriguez Barradas; Cynthia Gibert; David Leaf; Sheldon T Brown; Jeffrey Samet; Lewis Kazis; Kendall Bryant; Amy C Justice Journal: Circ Cardiovasc Qual Outcomes Date: 2011-06-28
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Hiroyu Hatano; Rebecca Scherzer; Yuaner Wu; Kara Harvill; Kristinalisa Maka; Rebecca Hoh; Elizabeth Sinclair; Sarah Palmer; Jeffrey N Martin; Michael P Busch; Steven G Deeks; Priscilla Y Hsue Journal: J Acquir Immune Defic Syndr Date: 2012-11-01 Impact factor: 3.731
Authors: Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal Journal: N Engl J Med Date: 2008-03-27 Impact factor: 91.245
Authors: H-J Epple; T Schneider; H Troeger; D Kunkel; K Allers; V Moos; M Amasheh; C Loddenkemper; M Fromm; M Zeitz; J-D Schulzke Journal: Gut Date: 2008-10-20 Impact factor: 23.059
Authors: Dima A Hammoud; Sanhita Sinharay; Sally Steinbach; Paul G Wakim; Katrina Geannopoulos; Katherine Traino; Amit K Dey; Edmund Tramont; Stanley I Rapoport; Joseph Snow; Nehal N Mehta; Bryan R Smith; Avindra Nath Journal: Neurology Date: 2018-09-26 Impact factor: 9.910
Authors: Márton Kolossváry; Elliot K Fishman; Gary Gerstenblith; David A Bluemke; Raul N Mandler; David Celentano; Thomas S Kickler; Sarah Bazr; Shaoguang Chen; Shenghan Lai; Hong Lai Journal: Eur Radiol Date: 2021-03-03 Impact factor: 7.034
Authors: Fernando Guerrero-Pinedo; Laura Ochoa-Zárate; Camilo J Salazar; Diana Cristina Carrillo-Gómez; Manuel Paulo; Liliana Janeth Flórez-Elvira; Jorge Guillermo Velasquez-Noreña Journal: SAGE Open Med Date: 2020-06-17
Authors: Kathleen F Walsh; Myung Hee Lee; Shoria Martelly; Marie Melissa Pierre; Junon Joseph; Myrlene Gustin; Robert N Peck; Daniel W Fitzgerald; Jean William Pape; Margaret McNairy Journal: J Clin Hypertens (Greenwich) Date: 2018-09-26 Impact factor: 3.738